Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory...

Area of Science:

• Nephrology
• Pharmacology
• Oxidative Stress Research

Background:

• Tacrolimus (FK506) is a vital immunosuppressant post-kidney transplant.
• Nephrotoxicity is a significant clinical challenge associated with tacrolimus therapy.
• Understanding FK506-induced glomerular injury mechanisms is crucial for developing protective strategies.

Purpose of the Study:

• To investigate the mechanisms underlying FK506-induced glomerular injury.
• To evaluate the renoprotective potential of telmisartan against FK506 nephrotoxicity.
• To explore the role of oxidative stress and NAD(P)H oxidase in FK506-mediated kidney damage.

Main Methods:

• Wistar rats were assigned to vehicle, FK506, or FK506 + telmisartan groups.
• Kidney function, morphology, and oxidative stress markers were assessed.
• In vitro studies utilized human glomerular endothelial cells (hGECs) to examine FK506 effects on reactive oxygen species (ROS).

Main Results:

• FK506 treatment increased glomerular reactive oxygen species (ROS) production via NAD(P)H oxidase activation.
• FK506 elevated ICAM mRNA expression, leading to macrophage infiltration in glomeruli.
• Telmisartan cotreatment significantly inhibited NAD(P)H oxidase activity and reduced ROS production.

Conclusions:

• FK506-induced glomerular injury is mediated by oxidative stress through NAD(P)H oxidase activation.
• Telmisartan demonstrates renoprotective effects by counteracting FK506-induced oxidative stress.
• Telmisartan's antioxidative properties offer a promising therapeutic approach for FK506 nephrotoxicity.